Intravenous nitroglycerin (glyceryl trinitrate, GTN) has been used as an anti-ischemic agent for the therapy of unstable angina, acute myocardial infarction and postinfarction angina. Nitric oxide (.NO) and S-nitrosothiols (SNO) constitute the biologically active species formed via nitroglycerin bioactivation. The clearance rates of nitroglycerin greatly exceed hepatic blood flow with known extrahepatic metabolism being present in red blood cells (RBCs) and vascular wall. Increased levels of reactive oxygen species (ROS) formation can diminish the therapeutic action of organic nitrates by scavenging donated .NO and oxidizing tissue thiols important in nitrate biotransformation. In vivo and in vitro studies reported herein show that red cell activity of antioxidant enzymes, catalase (CAT) and glutathione peroxidase (GPx), are significantly decreased after intravenous nitroglycerin treatment and incubation with GTN. Catalase activity (739.6 ± 92.3 k/grHb) decreased to 440.1 ± 111.9 and 459.8 ± 130.7 k/grHb after 1 and 24 hr GTN infusion, respectively. Similarly, seleniumGPx activity (5.8 ± 1.8 U/grHb) decreased to 3.2 ± 1.7 and 3.8 ± 1.1 U/grHb after 1 and 24 hr GTN infusion, respectively. The reported decrease in red cell antioxidant enzyme activities can generate an oxidant milieu which can lead to a rapid inactivation of nitroglycerin-donated .NO and cause oxidation of tissue thiols important in nitrate biotransformation. [ 
43] CO-CULTURE OF SKELETAL MYOBLASTS AND MESENCHYMAL STEM CELLS TO AUTOLOGUE TRANSPLANT TREATMENT OF THE CARDIAC INSUFFFICIENCY IN RATS.
Carvalho KAT, Rebellato CLK, Senegaglia AC, SouzaGuarita LC, Hansen P, Cury CC, Francisco JC, Scorsin M , Brofman PRS.
Introduction: Currently, two lines of research are being proposed in treatment of cardiac insufficiency in an attempt to address the main cause: skeletal myoblast transplant which increases contractile muscular mass and mesenchymal stem cells transplant which increases neoangiogenisis. Our objective is to develop a cocultivation method of skeletal myoblasts and mesenchymal stem cells for an autologous co-injection. Method: Skeletal myoblast and mesenchymal stem cells of 10 rats were isolated and co-cultivated. We used DMEM medium, with 10% Fetal Calf Serum (FCS), 1% ATB and growth factors. The cultures were maintained in incubator with 5% CO2 at 37°C. Assays were performed in culture flasks and the cells plated initially in variable proportions, skeletal myoblasts/mononuclear cells: 2:1; 1:1; 1:2, respectively and morphological observations were made regarding the cell survival, adhesion to substrate and confluence. The proportion 2:1 had a better cellular proliferation and the cells were co-cultivated in a concentration of 5 X 105/ ml, during 14 days. After 48 hours no adherent cells were aspirated from the flasks, just resting adherent cells: myoblasts and mesenchymal stem cells.
The medium was exchanged 2-3 times a week during the culture period. The identification of the cells in culture were made using fast myosin and vimentine proteins by immunocytochemistry . Results: Both cells types proliferated and expanded in the same conditions with yield of 5,5 x 107 (1,6 x 107-5, 4 x 108). The cells were positive for fast myosin and vimentine by proteins. Conclusion: The co-culture of skeletal myoblasts and mesenchymal stem cells has shown to be an efficient method of co-cultivation, since the cells were able to proliferate together under the same conditions and with a good yield, creating the possibility of cellular interaction in vitro and perhaps in vivo.
[44] PUMPING CAPACITY OF BIOMECHANICAL HEARTS (BMH) WITH VALVE HOMO-GRAFTS AND TANGENTIAL SQUEEZING NW Guldner, P Klapproth, M. Marmoodi, Ch. Enzensberger, M Großherr, R Noel,
H-H-Sievers

Clinic of Cardiac Surgery University of Schleswig Holstein Campus Lübeck Germany
Background In a valve bearing BMH model supplying failing goat hearts, two heart valves showed to be most effective for pumping. Furthermore linear muscle contractions are known to transfer much more power than concentric contractions in skeletal muscle ventricles (SMV). Because linear muscle contractions in SMVs are not possible, a tangential squeezing should become applied as a compromise between linear and concentric contractions. An intra-operative stimulation setting with different intervals from R-waves should become evaluated for maximal stroke volumes. Methods In 6 adult African Bore bocks, left latissimus dorsi muscle (LDM) was electrically pre-conditioned for two weeks and then wrapped around a pumping chamber of a Biomechanical Heart (BMH). LDM was fixed at the internal left thoracic wall and the muscle contracted concentrically as well as tangentially. The muscle's origin was fixed externally to the thorax by an artificial tendon. Inlet and outlet of the chamber beard aortic and pulmonal valve-homografts. An ultrasonic flow probe was placed around the aorta caudal the BMH. Intra-operatively, a conductance catheter was placed within the pumping chamber for stroke volume evaluation and pumping function was additionally documented by X-ray examination.
Results Valve homografts and tangential mechanical squeezing of the pumping chamber are feasible in a chronic big animal model with good results in stroke volumes, which ranged from 2.3 ± 0.6 L/min to 3.1 ± 0.7 L/min with a BMH support in a 1:3 mode, measured by the conductance catheter method and visualized by ventriculo-graphy. A burst setting of 300 msec after the R-wave induced the highest stroke volumes, documented by ultrasonic flow measurements. Conclusion Valve homografts, tangential mechanical squeezing and a defined stimulation intervals from the R-wave are a remarkable functional improvement in a preclinical big animal model of Biomechanical Hearts.
[ The use of skeletal myoblast in patients with intramyocardial infarction may result in improved function. Methods: 13 patients with old MI and ischemic coronary disease were treated with CABG and intramyocardial injection of autologous skeletal myoblast cultured with autologous serum. Global and regional cardiac function was assesed by 2D and ABD echocardiogram. 18F-FDG and 13N-amonia PET studies were used to determine perfusion and viability. Results: All patients have been discharged from the hospital and are alive. Skeletal myoblast implant was not associated with prolongation of post-surgical hospitalization or increased incidence of surgical complications. No significant increase in cardiac arrythmias was detected after skeletal myoblast implant. In fact, the frequency of premature ventricular beats was reduced after surgery. LEVF was increased from 35 + 2% before surgery to 53+5% at tree months (p=0.05). The median number of akinetic/hypokinetic segments before surgery was 7 and was reduced to a median of 3 (0-5) (p= 0.01). Regional contractility revealed a profond improvement in those cardiac segments treated with skeletal myoblast (wall motion score index 2.64 at baseline versus 1.64 at 3 months, p = 0.005). Quantitative 18F-FDG PET studies demonstrate a significant (p= 0.05) increased in cardiac viability in the infarct zone 3 months after surgery. No significant differences were found for 13N-amonia PET studies. Conclusions: In patients with old myocardial infarction, treatment with skeletal myoblast in conjunction with CABG is safe and feasible and is associated with an increased global and regional LV function and improvement in the viability of cardiac tissue in the infarct area.
The current techniques such as Holter and Rtest are partially efficient to diagnose the cardiac arrhythmia because they are limited in time (24h for the Holter and one week for the Rtest). Furthermore, the telemetry cardiac arrhythmia system (for example Agilent) is expensive and limited in space because in general, it is only installed at hospital. So a new technique is proposed to remedy the previous drawbacks and to improve the accuracy and the efficiency of the diagnostic of ventricular tachycardia among the high risk patients to enable to propose the implantation of Implantable Cardioverter Defibrillator to prevent sudden death. A platform containing a local server connected to a Wireless ECG Sensor based on Bluetooth or IEEE802.11b and a remote surveillance server dedicated to the remote continuous cardiac arrhythmias detection and monitoring over Internet is implemented and evaluated. To realise a low cost, low energy consumption and compact wireless ECG sensor (WES) responding to the last AHA recommendation, the embedded basic technologies such as distributed real-time fault tolerant micro kernel, dedicated hardware and firmware and real-time TCP/IP protocol stack are implemented. The patient is equipped with a compact and portable (credit card format) wireless ECG sensor allowing the capture of 4 leads of ECG signals sampled at 500Hz and he may be filmed continuously by a low cost WEB camera: WEBCAM (indoors). The ECG signals are sent to a local server and will be processed to detect cardiac arrhythmias. The WES allows two operation modes: real-time and deferred. In real-time mode, the WES may be configured to send continuously the ECG signals and the anomalies to the remote server; this configuration is adapted to the remote diagnostic but it is not adapted to monitor and to survey a large number of patients. For the remote monitoring, the WES may be configured to send the ECG signals only when a cardiac arrhythmia event is detected. The events to be sent are defined by the cardiologist. In this case, a message including a sequence of ECG signals (pre and post anomaly) and the images of the patient (indoors only) are sent immediately and automatically to the remote surveillance server. So according to the gravity of the symptom, cardiologist or physician can intervene in real-time or lately. To assure the processing of emergency message and real-time visualization of ECG signal, messages are classified into three levels: high (emergency message…), medium (ECG signal …) and low (image …). Thus with an adaptive algorithm tuning to the telecommunication traffic (especially low bandwidth medium), a classical MODEM (56Kbps) allows remote real-time visualization of 4 leads ECG signals. When the patient is at home, its images may be sent to the remote server but not in video rate, because the image is a low level message and bandwidth consuming, thus it is sent only when the network traffic is favourable. Whereas in deferred mode, a report similar to a Holter report is sent periodically (for example once a day). Furthermore, the patient may be contacted through Internet by the cardiologist anywhere and any time and the WES may be remotely reconfigured if necessary according to the patient state. When the network traffic is disturbed, ECG signals are temporally saved on the WES. The WES can save continuously 4 leads of ECG signals sampled at 500Hz during 24h. Our platform allows continuous remote cardiac arrhythmias monitoring and permits the patient to lead a normal life indoors and outdoors thus it is more efficient to diagnose cardiac arrhythmias. Currently the platform including a WES, a local server and the remote server, is evaluated at CHU of hospital of Gabriel Montpied at Clermont-Ferrand in FRANCE. The cardiac arrhythmias detection results are similar to the HP telemetry system ones evaluated on about ten patients. It is also evaluated by using MIT-BIH cardiac arrhythmias data base, the average cardiac arrhythmias detection is about 95%. We are working on the implementation of Intelligent Wireless ECG Sensor (IWES) by integrating the cardiac arrhythmia detection algorithm on a chip (ICAC). The ICAC is currently under evaluation and test on an FPGA. Thus the new platform contains a set of IWES and a remote server and it will be more reliable and friendly used. Enhanced external counterpulsation (EECP) has been shown to reduce angina and ischemia in patients with coronary artery disease. EECP involves sequential inflation and deflation of compressive cuffs wrapped around the lower extremities. These sequential events may increase diastolic aortic pressure and cardiac output and decrease cardiac afterload. This therapy may represent a valuable alternative for symptomatic patients despite an optimal medical treatment who cannot benefit for a conventional revascularisation by angioplasty or coronary artery by pass. Mechanisms who underlying these improvements include mechanical support as like intra aortic balloon with an increase in coronary blood flow, and other beneficial effects on endothelial function, opening or expansion of collateral vessels and a possible peripheral conditioning. However these mechanisms are poorly understood. We conduct a study including two populations of patients: asymptomatic high cardiovascular risk and confirmed stable coronary patients. High risk patients underwent only one session, coronary artery disease patients underwent 35 sessions of EECP therapy according the classical treatment protocol. Patients were randomized in two groups: sham-control EECP and active treatment. We proposed preliminary results concerning the acute effects of EECP. This study investigates the effect of a single session of EECP in left ventricular filling evaluated by Doppler echocardiography and cGMP levels measured by radio immunoassay in whole blood, platelet-rich plasma and isolated platelets. For this purpose we performed a Doppler echocardiography and a blood sampling before and just after the (first) EECP session. Twenty patients were included in the echocardiographic study: 6 underwent a "low" (inactive) external pressure session and 14 a "high" (active) pressure treatment. After EECP session, in patients treated by EECP, peak of E wave decreased significantly, deceleration time is prolonged but this trend is not statistically significant. None of these effects was observed in patients of inactive group.
Eighteen patients had blood samplings in order to asses cGMP and evaluate their endothelial function. Whole blood and platelets contents of cGMP increase significantly one hour after EECP treatment. Inhibition of NO synthesis by L-NMMA reduce cGMP after EECP whereas superoxide dismutase catalase increase the cGMP platelet contents after EECP. These results indicate that EECP activates NO pathway. Our preliminary results suggest that the mechanisms underlying the beneficial effects of EECP may result from several potential effects. Among these effects, hemodynamical improvement of diastolic function and activation of NO pathway by acute shear stress stimuli may participate in the improvement in symptoms and exercise tolerance described in chronic treatment by EECP. Further investigations need to be performed for determine the complex interrelationship of cardiac and peripheral effects of this therapy. Background : Exercise training improves exercise tolerance in chronic heart failure (CHF) patients. Recently, cardiac resynchronization has been shown also to increase functional capacity in CHF patients with intraventricular conduction delay. The aim of this pilot study was to assess complementary effects of these two non-pharmacological approaches to optimize both hemodynamic and symptomatic improvements. Methods: We studied 8 CHF pts (mean age: 67 ± 7 years, 7 men, mean LVEF: 0.18 ± 0.08 ) who underwent 18 ± 8 sessions of exercise training after bi-ventricular pacing implantation. Exercise tolerance were evaluated before and after pace-maker implantation, and at the end of the rehabilitation. Results: § = p<0.05 before-after PM, * = p<0.05 before PM-after training, # = p<0.05 after PM-after training Conclusion: Exercise training after cardiac resynchronization provides additional improvement in effort tolerance in CHF patients. These preliminary results encourage to perform a randomized study to evaluate benefits of combined strategy (resynchronization and exercise training) compared to resynchronization therapy alone in CHF patients.
[49] LONG TERM RESULTS AFTER CARDIOMYOPLASTY.
O JEGADEN, F DELAHAYE, F FARHAT, P MONTAGNA, P MIKAELOFF
L. PRADEL Hospital, Cl. BERNARD University, INSERM 0226 LYON -FRANCE
Cardiomyoplasty (CMP) was proposed as a palliative treatment in congestive heart failure. Long term survival and functional outcome after CMP were analysed in a series of 21 consecutive patients. Between December 1989 and February 1997, a CMP procedure was performed in 21 male patients with a mean age of 56 years. All patients were in NYHA class III; 10 patients had ischemic cardiomyopathy and 11 had primary dilated cardiomyopathy. Reinforcement CMP was isolated in 12 patients and associated with a cardiac procedure in 9. There was no perioperative death and all patients were discharged from hospital. Four patients had heart transplantation: 8, 9, 11 and 26 months after CMP. In July 2003 the mean follow-up was 6±1 years. There were 16 deaths: heart failure 8, sudden death 5, death after transplantation 3. The actuarial survival was 52±22 % at 5 years and 23±20 % at 10 years; it was better in primary than in ischemic cardiomyopathy : 64±29 % vs 40±31 % at 5 years and 41±33 % vs 10±19 % at 10 years (p<0.001). The probability to be free of CMP failure (death or transplantation) was 43±21 % at 5 years and 22±19 % at 10 years. The probability to be free of acute congestive heart failure after CMP procedure was 71±20 % at 3 years, 59±23 % at 5 years and 31±26 % at 10 years; it was better in primary than in ischemic cardiomyopathy: 70±29 % vs 52±31 % at 5 years. Five patients were still alive: 4 patients 10, 10.5, 12.5 and 13 years after isolated CMP were in NYHA class II, II, III, III respectively; and 1 patient 6.5 years after CMP and then transplantation was in class 2. CMP seems to have been useful for patients in comparison with medical treatment but less than heart transplantation. The occurrence of sudden death often in patients with good functional results hid the benefit of the procedure. CMP was more liable to stabilize primary than ischemic cardiomyopathy. Good functional outcome observed more than 10 years after the surgery point to a possible renewal of this surgical concept.
[ Background: We initiated clinical study to determine safety and activity of gene encoding vascular endothelial growth factor(VEGF) 165 administered directly into the myocardium as the only treatment and during coronary artery by pass grafting operation (CABG). Our trials with the plasmid encoding VEGF165 shows that intramyocardial application is safe and patients have benefited with the therapy. Methods: VEGF gene transfer was performed in 31 patients (29 male, 2 female, ages from 48 to 73 years old). 200µg of the plasmid encoding VEGF165 was injected into the ischaemic,viable myocardium that could not be surgically revascularized in patients undergoing CABG and 400µg in patients without CABG. Patients with ejection fraction (%EF) < 30%, fertile females, acute myocardial infarction (MI), retinopathy and neoplasms were excluded from the study. 15 patients had performed CABG, in 16 cases there was no possibility of CABG because of surgical limitations and the application of genes encoding VEGF165 was the only solution. %EF, myocardial perfusion, ECHO, angiogram, ventriculography, quality of life and nitroglycerin consumption were evaluated pre-and postoperatively. Results: The most of patients tolerated surgery uneventfully, in both groups of patients 2 deaths occurred. In three cases the evidence of myocardial infarction was noted. %EF improvement haven't been noticed so far. Most of patients were angina free at 6 months after surgery. Patients reported much better quality of life and reduction of nitroglycerin use. A reduction in ischaemic defects on SPECT scans were observed, particularly on rest SPECT scans. In some of patients agiography revealed improved collateral filling. Conclusions: Direct myocardial administration of genes encoding VEGF165 can be an effective method of treatment patients with chronic and advanced coronary artery disease either as a supplementary or as a sole therapy.
[51] A MECHANICAL VALVE FOR LVAD DESTINATION THERAPY?
By Sidney Levitsky, M.D.
Boston, MA, USA
One of the troubling aspects of LVAD development has been the valvular components of the devices. Tissue valves have had durability problems that limit longerterm usage associated with destination therapy.
Mechanical valves have problems with hemolysis and thromboembolism, may require higher levels of anticoagulation, and suffer from potential cavitation damage. A mechanical valve appropriate for destination therapy must have exceptional flow dynamics, be minimally damaging to the blood, be resistant to cavitation damage and allow reduced levels of anticoagulation. The On-X valve, developed for standard valve replacement therapy in the late 1990's, has properties that make it a promising candidate for trial in LVAD destination therapy. Bench studies have demonstrated a higher threshold for cavitation. Clinical studies of the valve have shown it to have superior hemodynamics with a 19mm valve mean gradient of 9 mmHg and an effective orifice area of 1.5 cm2. Combined with this flow advantage is a low propensity for blood damage with postoperative LDH values in the normal range even in double valve replacement and low rates of thromboembolism especially in the face of erratic anticoagulation control. A clinical study in a poorly-anticoagulated South African population of over 200 mainly mitral or double valve replacement patients, with up to 3 years of follow-up and approximately 20% of the population not anticoagulated at all, has produced no thrombosed valves and only one thromboembolic event to date. Clinical results indicate a real opportunity for reduced anticoagulation and have prompted the start of a study of the valve using aspirin only for anticoagulation. This background has also led to the initiation of tests of the On-X valve in several LVAD platforms for destination therapy. We performed a valve repair in 12 patients with the following procedure: after standard left atriotomy, an incision was made to detach from the annulus the tethered segment of the PML (generally at P2-P3 level). Secondary chordae were transacted to increase leaflet mobility. The involved portion of the annulus was plicated with interrupted sutures. The residual defect of the leaflet surface was closed suturing the margins not to the annulus but between them in order to increase the area of the PML. Finally the plicated annulus was reinforced with a Gore-Tex strip. Coronary revascularization and left ventricular reshaping (Dor procedure) were added when clinically required. Results One hospital death was recorded (8%) and 1 patient (8%) underwent early mitral valve replacement. In all patients immediate postoperative echocardiography showed good results (MR less than grade 1) and no systolic anterior motion was detected. At the mean follow-up of 17 ± 6,5 months (range 3-31) no valve related events were registered and 9/11 patients (82%) were in NYHA I-II. At early post-discharge echocardiographic control 8/11 patients (73%) showed trivial or no MR. Conclusions The procedure restores mitral geometry toward a correct annular diameters ratio, it repositions the tethering leaflet acting on P2-P3 annulus and PML area is extended to achieve a better coaptation. Moreover a posterior reinforcing band preserves the dynamic motion of the annulus ideally allowing better ventricular function.
Immediate results are encouraging but further study will be required to assess repair durability and patients' outcome.
[
53] CARDIAC RESYNCHRONIZATION THERAPY AFTER CABG IN PATIENTS WITHOUT LEFT BRANCH BLOCK
Oertel, F., Raab, S., Weimann, T., Fink, M., Beyer, M.
Department of Cardiac Surgery, Klinikum Augsburg, Augsburg, Germany
Cardiac Resynchronization Therapy (CRT) has proved to be good treatment for patients suffering from myocardial insufficiency and left branch block. Recent studies show that this therapeutic option should not be limited to patients with this ECG abnormality. Our aim was to show that patients, especially the ones with a poor ejection fraction, profit from this therapeutic option after CABG. Three groups (20 patients each), all without left branch blocks, underwent elective CABG. The first two groups had poor ejection fractions (< 35%). But only one of both groups received permanent biventricular stimulation for seven days after surgery. The third group consisted of patients with good ejection fractions. They also received continuous biventricular stimulation. Before and on the first, third, seventh and tenth day after the surgical treatment the following parameters were established: left ventricular function obtained through transthoracic echocardiography, myocardium-specific enzymes (Creatininkinase and Isoenzyme), Brain Natriuretic Peptide (BNP) and ECG. No patient had a preoperative left branch block or developed one after CABG. Our first results (n = 36) indicate a significant improvement (p<0.002) in left ventricular function for patients with poor ejection fractions during biventricular pacing. Due to these better ejection fractions the patients only stayed in ICU up to 2 days. Only one patient in this group did not benefit from biventricular pacing. Without biventricular pacing after CABG the left ventricular functions of patients with poor ejection fractions were reduced even more (p=0.05) in the early postoperative days. Patients with a good left ventricular function did not benefit from biventricular pacing. With them, there even was a decrease in left ventricular function during biventricular pacing. The evaluation of BNP after CABG was similar to these results of left ventricular function. Patients with a poor ejection fraction, who received biventricular stimulation, reached near-preoperative BNP-levels on day 10. In contrast to this, patients who did not receive biventricular stimulation did not show any decrease in BNP-levels until postoperative day 10. We conclude that patients with a poor left ventricular function benefit most from biventricular pacing in the early postoperative days. To us there is indication for this therapy in patients who suffer from an ischemic myocardial dilatation. A left branch block is not necessary. But echocardiographic analysis showed an improvement of the left ventricular contraction similar to the one observed in patients who received cardiac resynchronisation therapy due to a left branch block. We explain our results in the following way: Our patients do not suffer from a block in Tawara branch but from one further downstream in the dilated ventricular myocardium.
We recommend that these patients should receive a permanent CRT. In our opinion there are the following criteria for the implantation of a biventricular pacing device: poor ejection fraction (< 35 %), ischemic myocardial dilatation, postoperative benefit from nonpermanent biventricular pacing and decrease of BNPlevel during biventricular pacing before day 10. These patients should receive a permanent epicardial lead implanted on the left ventricle during CABG procedure. About ten days after CABG a permanent CRT device should be implanted. Therefore we implant a rightatrial and rightventricular lead transvenously and we use the leftventricular epicardial lead for leftventricular stimulation.
[ Objective: The transcription factor nuclear factor kappa B (NF-kB) plays an important role in the inflammatory response following myocardial infarction (MI). We hypothesized that NF-kB-blockade by gene-therapeutic overexpression of its inhibitor Inhibitor KappaB alpha (IkB) in an animal model of acute ischemia reduces the inflammatory response and therefore reduces ventricular remodeling. Methods: MI was induced in male Sprague-Dawley-rats by ligation of the LAD and followed by adenovirusmediated intramyocardial delivery of IkB-gene (n=12) respectively of a LacZ-reporter-gene (n=12). Shamoperated animals (n=12) received neither ligation nor gene transfer. 5 days after MI IkB-expression and tissue levels of TNF-alpha and IL-1beta were determined by westernblotting. Seven weeks after MI cardiac function was evaluated by transthoracic echocardiography and pump function curves on an isolated working heart. Results: In the treatment group IkB-Levels were 5,95fold higher whereas TNF-alpha and IL-1beta protein levels were significantly reduced by 72,6% and 73,2%, respectively, in the remote area compared to p<0, 05 Before selective myocardial revascularisation became possible a transplantation of pedicled muscle flaps onto hearts was performed to enhance myocardial blood supply. This method continually gains importance as the number of patients with intractable angina still increases. First we gained experience with this method in dogs with artificially produced myocardial infarction of the anterior wall. Four weeks later a free pectoralis muscle flap was transplanted onto the anterior wall of the heart. Arterial blood supply was achieved with an anastomosis with the internal mammary artery. The venous flow was drained into the right atrium. Four to eight weeks after surgery, the patency of the anastomosis was evaluated by angiography, showing patency in almost all surviving animals. Histological examination of the hearts revealed a prominent vascular network penetrating into the underlying myocardium. Corrosion cast preparations, as well as a post-mortem angiography, showed even further penetration of the neovessels into the non-injured parts of the myocardium. Due to these good results in animals we started to perform this indirect myocardial revascularisation in patients suffering from untreatable angina pectoris. All of them were not suitable for coronary artery bypass grafting due to small-vessels disease. The upper part of the musculus latissimus dorsi was isolated and removed together with its nutrient vessels. After exposition and roughening of the anterior wall of the heart the free muscle flap was positioned in this area and fixed with only a few epicardial sutures. Afterwards the artery of the muscle flap was anastomosed to the stump of the left IMA. The vein of the muscle flap was inserted into the right atrium. Since 1991 26 patients have undergone this procedure. During a six-month follow-up all the patients confirmed that their overall state had improved. In angiography all anastomoses save two proved to be open. The contrast medium injected into the left IMA showed hazy contrasting of the anterior wall of the heart. The venous drainage to the right atrium was done mainly via the sinus coronarius. The myocardial nuclear scintigraphy showed good perfusion of the anterior wall of the heart. The last questionnaire was done in January 2003 with an overall experience of 117.25 years. 83% of the patients confirmed to be free of angina pectoris or suffer only from heavy exertion. The classification of NYHA showed even better results. Only one patient mentioned some deterioration in his comfort but in no patient had any myocardial infarction occurred since surgery. 
